Prognostic value of circulating tumor cells in nonmuscle invasive bladder cancer: a CellSearch analysis.

Circulating tumor cells (CTCs) provide prognostic information in patients with metastatic tumors. Recent studies have shown that CTCs are released in circulation in an early phase of cancer disease so that their presence is under investigation in the adjuvant setting. Few studies investigated the prognostic significance of CTCs enumeration in patients with metastatic and advanced bladder cancer. The current study has analyzed the presence of CTC in patients with nonmuscle-invasive bladder cancer (NMIBC).

Forty-four NMIBC patients were enrolled and included in a 24-month follow-up program. Blood drawings were carried out in all patients at the first diagnosis. CellSearch system (Veridex; LLC, Raritan, NJ) was used for CTCs enumeration.

CTC were detectable in 8/44 patients (18%). Presence of CTC was found significantly associated to shorter time to first recurrence (6.5 versus 21.7 months, P<0.001). Median time to progression was not reached, due to the short follow-up period. CTC presence was found associated to concomitant carcinoma in situ and higher T category.

The detection of CTC in this setting of disease may allow to distinguish patients with high risk of recurrence from those with high risk of progression, as well as to early identify patients candidate for adjuvant treatment.

Annals of oncology : official journal of the European Society for Medical Oncology. 2019 Dec 04 [Epub]

P Gazzaniga, A Gradilone, E de Berardinis, G M Busetto, C Raimondi, O Gandini, C Nicolazzo, A Petracca, B Vincenzi, A Farcomeni, V Gentile, E Cortesi, L Frati

Departments of Molecular Medicine. Electronic address: ., Departments of Molecular Medicine., Departments of Gynecology, Obstetrics and Urological Sciences, Division of Urology, Sapienza University, Rome., Division of Medical Oncology, Campus Biomedico University, Rome., Departments of Public Health and Infectious Diseases., Radiological, Oncological and Pathological Sciences, Division of Oncology, Sapienza University, Rome, Italy.